scholarly journals Exploring Response to Immunotherapy in Non-Small Cell Lung Cancer Using Delta-Radiomics

Cancers ◽  
2022 ◽  
Vol 14 (2) ◽  
pp. 350
Author(s):  
Emanuele Barabino ◽  
Giovanni Rossi ◽  
Silvia Pamparino ◽  
Martina Fiannacca ◽  
Simone Caprioli ◽  
...  
Keyword(s):  
Lung Cancer ◽  
Small Cell Lung Cancer ◽  
Cell Lung Cancer ◽  
Small Cell ◽  
Response To Therapy ◽  
Ct Scans ◽  
Absolute Difference ◽  
Relative Reduction ◽  
Small Cell Lung ◽  
Lung Lesions

Delta-radiomics is a branch of radiomics in which features are confronted after time or after introducing an external factor (such as treatment with chemotherapy or radiotherapy) to extrapolate prognostic data or to monitor a certain condition. Immune checkpoint inhibitors (ICIs) are currently revolutionizing the treatment of non-small cell lung cancer (NSCLC); however, there are still many issues in defining the response to therapy. Contrast-enhanced CT scans of 33 NSCLC patients treated with ICIs were analyzed; altogether, 43 lung lesions were considered. The radiomic features of the lung lesions were extracted from CT scans at baseline and at first reassessment, and their variation (delta, Δ) was calculated by means of the absolute difference and relative reduction. This variation was related to the final response of each lesion to evaluate the predictive ability of the variation itself. Twenty-seven delta features have been identified that are able to discriminate radiologic response to ICIs with statistically significant accuracy. Furthermore, the variation of nine features significantly correlates with pseudo-progression.

SERUM NEURON-SPECIFIC ENOLASE: A MARKER FOR DISEASE EXTENT AND RESPONSE TO THERAPY OF SMALL-CELL LUNG CANCER

The Lancet ◽  
1982 ◽  
Vol 319 (8272) ◽  
pp. 583-585 ◽  
Author(s):  
DesmondN Carney ◽  
DanielC Ihde ◽  
MartinH Cohen ◽  
PaulJ Marangos ◽  
PaulA Bunn ◽  
...  
Keyword(s):  
Lung Cancer ◽  
Small Cell Lung Cancer ◽  
Cell Lung Cancer ◽  
Neuron Specific Enolase ◽  
Small Cell ◽  
Response To Therapy ◽  
Small Cell Lung ◽  
Disease Extent ◽  
Serum Neuron Specific Enolase

Evaluation of three biochemical markers for serially monitoring the therapy of small-cell lung cancer.

1987 ◽  
Vol 5 (3) ◽  
pp. 472-479 ◽  
Author(s):  
P A Ganz ◽  
P Y Ma ◽  
H J Wang ◽  
R M Elashoff
Keyword(s):  
Lung Cancer ◽  
Small Cell Lung Cancer ◽  
Cell Lung Cancer ◽  
Biochemical Markers ◽  
Small Cell ◽  
Response To Therapy ◽  
Small Cell Lung ◽  
Single Institution ◽  
Limited Disease ◽  
Acid Glycoprotein

A number of biochemical markers have been proposed for monitoring the therapy of small-cell lung cancer (SCLC). This report reviews the experience at a single institution using three biochemical markers, alpha-1-acid glycoprotein (AGP), carcinoembryonic antigen (CEA), and lactate dehydrogenase (LDH), for serially monitoring the therapy of patients with SCLC. AGP measurements identified limited-disease patients more frequently than LDH or CEA, and a combination of markers (AGP and LDH) improves the accuracy of correctly classifying patients with active disease. Each of the markers correctly tracked the clinical response to therapy in approximately two thirds of the subjects. The use of a combination of markers should be considered for monitoring the therapy of SCLC in future clinical trials.

MCM2 Is an Independent Predictor of Survival in Patients With Non–Small-Cell Lung Cancer

2001 ◽  
Vol 19 (22) ◽  
pp. 4259-4266 ◽  
Author(s):  
Nithya Ramnath ◽  
Francisco J. Hernandez ◽  
Dong-Feng Tan ◽  
Joel A. Huberman ◽  
Nachimuthu Natarajan ◽  
...  
Keyword(s):  
Lung Cancer ◽  
Small Cell Lung Cancer ◽  
Tumor Cells ◽  
Cell Lung Cancer ◽  
Small Cell ◽  
Response To Therapy ◽  
Positive Staining ◽  
Small Cell Lung ◽  
Proliferating Cells ◽  
Ki 67

PURPOSE: Minichromosome maintenance protein 2 (MCM2) is a component of the prereplicative complex. It is essential for eukaryotic DNA replication and is only expressed in proliferating cells. The prognostic utility of MCM2 compared with Ki-67, another marker of proliferating cells, on survival of patients with non–small-cell lung cancer (NSCLC) was studied. PATIENTS AND METHODS: We examined the immunohistochemical expression of MCM2 and Ki-67 in primary pathologic tumor specimens from 221 NSCLC patients. For each marker, the fraction of tumor cells with positive staining was assessed as a percentage and categorized into four groups: 0% to 24%, 25% to 49%, 50% to 74%, and ≥ 75%. MCM2 and Ki-67 immunoreactivities were compared with each other, and associations with pathologic and clinical parameters predictive of survival were analyzed with the χ2 test. Cox regression models were used to assess associations between MCM2 and Ki-67 and survival while controlling for confounders. RESULTS: Independent variables significantly associated with survival were tumor stage, performance status, and staining category. Patients with less than 25% MCM2 immunoreactivity had a longer median survival time than patients with ≥ 25% MCM2 immunoreactivity (46 v 31 months; P = .039) and a lower relative risk (RR) of death (RR, 0.55, 95% confidence interval, 0.34 to 0.88). There was no significant association between survival and Ki-67 expression. CONCLUSION: Immunostaining of tumor cells for MCM2 is an independent prognostic parameter of survival for patients with NSCLC. Interpretable results can be obtained on more than 96% of paraffin-embedded specimens, and approximately 35% will be in the favorable subgroup, with less than 25% positively stained tumor cells. Whether MCM2 is predictive of response to therapy needs to be studied.

Dosimetric consequences of tumor mobility in radiotherapy of stage I non-small cell lung cancer – an analysis of data generated using ‘slow’ CT scans

2001 ◽  
Vol 61 (1) ◽  
pp. 93-99 ◽  
Author(s):  
John R. van Sörnsen de Koste ◽  
Frank J. Lagerwaard ◽  
Regine H. Schuchhard-Schipper ◽  
Margriet R.J. Nijssen-Visser ◽  
Peter W.J. Voet ◽  
...  
Keyword(s):  
Lung Cancer ◽  
Small Cell Lung Cancer ◽  
Cell Lung Cancer ◽  
Small Cell ◽  
Stage I ◽  
Ct Scans ◽  
Small Cell Lung

Correlation between tissue PD-L1, TMB, and blood PD-L1, MSI biomarkers in patients with advanced-stage non-small cell lung cancer (NSCLC).

2020 ◽  
Vol 38 (15_suppl) ◽  
pp. e21564-e21564
Author(s):  
Sujitha Nandimandalam ◽  
Nitika Sharma
Keyword(s):  
Lung Cancer ◽  
Small Cell Lung Cancer ◽  
Cell Lung Cancer ◽  
Linear Correlation ◽  
Liquid Biopsy ◽  
Small Cell ◽  
Response To Therapy ◽  
Small Cell Lung ◽  
Tissue Biopsy ◽  
Bivariate Correlation

e21564 Background: Tissue biomarkers like programmed cell death ligand-1 (PD-L1), microsatellite instability (MSI) and high tumor mutational burden (TMB) are surrogates in identifying patients with non-small cell lung cancer (NSCLC) for treatment with immune checkpoint blockade (ICB) therapy. Although tissue biopsy is widely used for identifying the tumor biology, the invasive nature as well as insufficiency of tissue biopsy specimens limits its application. Liquid biopsy is a minimally invasive procedure and has gained interest in recent times for profiling cancer. We sought to study the correlation in the molecular tumor profile specifically PD-L1, MSI and TMB markers between the tissue and liquid biopsies. Methods: We conducted a retrospective review of patients with Stage 3, 4 and recurrent NSCLC that underwent tissue next generation sequencing (NGS) using Caris life sciences and liquid biopsy using Circulogene molecular diagnostics from January 2018 to December 2019 at East Carolina University. A total of 524 patients were reviewed out of which 199 patients had both liquid and tissue NGS performed at the time of initial diagnosis. TMB high was defined as greater than 10 mut/Mb whereas TMB low as less than or equal to 10 mut/Mb. PD-L1 was divided into negative (0%), 1-49% and ≥50%. The blood MSI was classified as positive or negative. We used frequency table, logistic regression and Pearson bivariate correlation for statistical analysis using SPSS platform. Results: The study cohort had 60% (n = 119) male and 40% (n = 80) female patients of which 53% (n = 105) were Caucasians and 45% (n = 89) were African Americans. A total of 87 patients (44%) had negative tissue PD-L1, 59 patients (30%) had tissue PD-L1 ≥ 50%. A linear correlation was seen between negative tissue PD-L1 and negative blood PD-L1 in 92% of patients (n = 80). However, only 15.3% (n = 9) had correlating tissue PD-L1 and blood PD-L1 ≥ 50%, p = 0.024. The negative blood MSI correlated to low tissue TMB in 83% ( n = 60) whereas positive blood MSI correlated to high tissue TMB in 25% (n = 19), p = 0.023. Conclusions: Our results indicate a linear correlation between tissue PD-L1 and blood PD-L1. Similarly, a linear correlation was seen between blood MSI and tissue TMB. Further studies are needed to elucidate the efficacy of ICB therapy using blood MSI and blood PD-L1 as biomarkers for response to therapy.

Stereotactic, high single-dose irradiation of stage I non-small cell lung cancer (NSCLC) using four-dimensional CT scans for treatment planning

Lung Cancer ◽  
2008 ◽  
Vol 60 (2) ◽  
pp. 193-199 ◽  
Author(s):  
Peter Fritz ◽  
Hans-Jörg Kraus ◽  
Thomas Blaschke ◽  
Werner Mühlnickel ◽  
Konstantin Strauch ◽  
...  
Keyword(s):  
Lung Cancer ◽  
Single Dose ◽  
Small Cell Lung Cancer ◽  
Treatment Planning ◽  
Cell Lung Cancer ◽  
Small Cell ◽  
Ct Scans ◽  
Small Cell Lung ◽  
Dose Irradiation ◽  
High Single Dose
Sign in / Sign up

Export Citation Format

Share Document